spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  targeted therapy 

 HSMN NewsFeed - 9 Jun 2023
Astellas Submits New Drug Application for Zolbetuximab in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Oct 2022
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 May 2022
Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Mar 2022
Roche announces collaboration with Bristol Myers Squibb to advance personalised healthcare through digital pathology solutions
Diagnostics
 HSMN NewsFeed - 29 Dec 2021
Ionis and AstraZeneca close deal to develop and commercialize eplontersen
Biopharmaceuticals
 HSMN NewsFeed - 7 Sep 2021
RenovoRx Receives New 510(k) Clearance for its RenovoCath(R) Delivery System Designed for Targeted Treatment of Solid Tumors
Devices Drug Delivery Oncology FDA
 HSMN NewsFeed - 6 Aug 2021
Medtronic to Acquire Intersect ENT
Devices Mergers & Acquisitions
 HSMN NewsFeed - 17 May 2021
Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 16 Apr 2021
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 5 Apr 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Biopharmaceuticals Neurology
 HSMN NewsFeed - 9 Mar 2021
Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)
Diagnostics Oncology FDA
 HSMN NewsFeed - 11 Feb 2021
Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 27 Jan 2021
Nuvalent Launches with $50M Series A Financing from Deerfield Management to Develop Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 8 Dec 2020
Amgen's Sotorasib Granted Breakthrough Therapy Designation for Advanced or Metastatic Non-Small Cell Lung Cancer Patients with KRAS G12C Mutation
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Biopharmaceutical Personnel
 HSMN NewsFeed - 18 Nov 2020
Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 25 Sep 2020
Blueprint Medicines Announces European Commission Approval of AYVAKYT(R) (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Sep 2020
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Sep 2020
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 25 Mar 2020
ArcherDX Receives Approval for Archer(R)MET Companion Diagnostic for TEPMETKO(R) (Tepotinib) in Advanced Non-Small Cell Lung Cancer in Japan
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 11 Feb 2020
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Dec 2019
OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Nov 2019
Armas Pharmaceuticals Announces Launch of Oncology Generic Erlotinib
Biopharmaceuticals Generics Oncology Product Launch
 HSMN NewsFeed - 11 Sep 2019
Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jul 2019
Recommendations for Personalised HCC Treatment With Y90 TheraSphere(TM) Published by an International Multidisciplinary Group
Devices Interventional Oncology
 HSMN NewsFeed - 3 May 2019
Caris Life Sciences Receives FDA Breakthrough Device Designation for MI Transcriptome(TM) Companion Diagnostic Test
Diagnostics Oncology FDA
 HSMN NewsFeed - 4 Apr 2019
DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Apr 2019
Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Feb 2019
FDA Approves Taiho Oncology's LONSURF(R) (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Dec 2018
BTG Announces National Reimbursement for TheraSphere(R) in France
Devices Oncology Reimbursement
 HSMN NewsFeed - 21 Nov 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Nov 2018
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Oct 2018
Thermo Fisher Scientific CE Marks Oncomine Dx Target Test
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 1 Oct 2018
Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 19 Sep 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Aug 2018
OncoSec Appoints Alain Algazi, MD, as Clinical Strategic Advisor
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jul 2018
FDA Grants Approval of TIBSOVO(R), the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jul 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jun 2018
Avella Selected by Array BioPharma Inc. to distribute BRAFTOVI(TM) (encorafenib) and MEKTOVI(R) (binimetinib)
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 5 Jun 2018
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Apr 2018
Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Dec 2017
Novartis' combination therapy Tafinlar(R) + Mekinist(R) granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 26 Sep 2017
CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Sep 2017
FDA approves Mylotarg for treatment of acute myeloid leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Jul 2017
Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for Progesterone Receptor Detection
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 8 Jun 2017
Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2017
CardioNXT Raises $2.1M For Atrial Fibrillation Led By Industry Veterans Bullock and Hawkins
Devices Cardiology Venture Capital
 HSMN NewsFeed - 31 May 2017
Array BioPharma And Ono Pharmaceutical Co., Ltd. Announce A License, Development And Commercialization Partnership For Two Novel Oncology Compounds, Binimetinib And Encorafenib
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Apr 2017
Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia
Biopharmaceuticals Gastroenterology Surgery Personnel
 HSMN NewsFeed - 29 Mar 2017
FDA Approves Genentech’s OCREVUS(TM) (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 3 Nov 2016
Eisai Welcomes Positive NICE recommendation for Halaven(R) (eribulin) for Patients with Locally Advanced or Metastatic Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Oct 2016
First Patient in Malaysia Receives TheraSphere(TM) Radioembolization Therapy
Devices Oncology
 HSMN NewsFeed - 17 Oct 2016
Teva Receives Positive Opinion from European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to Extend Indication of Trisenox(R) for First Line Treatment of Low- to Intermediate Risk Acute Promyelocytic Leukemia (APL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Oct 2016
Allergan plc Enters Into Licensing Agreement with AstraZeneca to Obtain Worldwide Rights to MEDI2070 Inflammatory Disorder Development Program
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 14 Sep 2016
European Commission Approves CABOMETYX(TM) (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Aug 2016
XALKORI(R) (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jul 2016
CellMax Life Raises $14M in Venture Funding, Launches Precision Cancer Testing Company for Early Detection & Optimal Management of Cancer
Diagnostics Personalized Medicine Venture Capital
 HSMN NewsFeed - 8 Jul 2016
William D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2016
Two-Year Study Results Show the Pulsante(R) Microstimulator Provides Sustained, Long-Term Relief for Cluster Headache Patients
Devices Neurology
 HSMN NewsFeed - 6 May 2016
ACT Genomics Raises $12.5 Million In Series B Funding
Diagnostics Oncology Venture Capital
 HSMN NewsFeed - 14 Apr 2016
RefleXion Medical Raises $46 Million Series B Financing Led by KCK Group
Devices Oncology Venture Capital Personnel
 HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
Biopharmaceuticals Personalized Medicine Oncology FDA
 HSMN NewsFeed - 4 Feb 2016
GenomeDx Publishes First Study Supporting Use of Decipher Test in Prostate Biopsy
Diagnostics Oncology
 HSMN NewsFeed - 11 Jan 2016
Tensha Therapeutics To Be Acquired By Roche
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Nov 2015
Pfizer Receives European Approval to Expand Use of XALKORI(R) (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Nov 2015
Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI(R) (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2015
GenomeDx Biosciences Adds Tina Nova and Craig Johnson to Board of Directors
Diagnostics Personalized Medicine Oncology Personnel
 HSMN NewsFeed - 30 Sep 2015
Blueprint Medicines Receives FDA Orphan Drug Designation for Novel Drug Candidate for Treatment of Hepatocellular Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Sep 2015
Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 29 Jun 2015
Mevion Medical Systems Delivers Proton Accelerator to Seidman Cancer Center at University Hospitals
Devices Oncology
 HSMN NewsFeed - 11 Jun 2015
Personal Genome Diagnostics Launches LungSelect(TM) For Non-Invasive Detection Of Clinically Actionable Mutations In Lung Cancer
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 12 May 2015
Aspyrian Therapeutics Inc. Announces FDA Acceptance of an Investigational New Drug Application for RM-1929, a First-in-Class, Precision-Targeted Therapy for Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Mar 2015
Jakavi(R) (ruxolitinib) Receives European Commission Approval as First Targeted Therapy for Patients with Polycythemia Vera
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Sep 2014
Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Sep 2014
Successful Completion of Phase III Program for Teva’s Reslizumab Two More Phase Iii Studies Support the Benefits of Reslizumab Treatment in Asthma Patients with Eosinophilia
Biopharmaceuticals
 HSMN NewsFeed - 30 Jul 2014
Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 27 Jan 2014
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Dec 2013
Celldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Oct 2013
BioMarker Strategies Names Jerry Parrott President and Chief Executive Officer
Diagnostics Personalized Medicine Oncology Personnel
 HSMN NewsFeed - 27 Aug 2013
Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 18 Jan 2013
Pfizer’s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Oct 2012
Roche Diagnostics ACCU-CHEK Combo Insulin Pump System Now Available in United States
Devices Monitoring Drug Delivery Endocrinology
 HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Jun 2012
Neuronetics, Inc. Receives CE Mark Approval for NeuroStar TMS Therapy
Devices Neurology Regulatory
 HSMN NewsFeed - 17 May 2012
Agilent to Acquire Dako for $2.2 Billion
Diagnostics Personalized Medicine Mergers & Acquisitions
 HSMN NewsFeed - 2 Apr 2012
MolecularMD Closes $6 Million Series B Financing and Announces Ensuing Growth Initiatives
Diagnostics Venture Capital
 HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jan 2012
Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2012
Spectranetics Strengthens Peripheral Vascular Portfolio with a Partnership to Distribute the TAPAS™ Catheter
Devices Distribution
 HSMN NewsFeed - 26 Aug 2011
U.S. Food And Drug Administration Approves Pfizer’s XALKORI(R) (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Aug 2011
FDA Clears Abbott's Genetic FISH Panel for Leukemia Patient Prognosis
Diagnostics Oncology FDA
 HSMN NewsFeed - 14 Jul 2011
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals
 HSMN NewsFeed - 5 Jul 2011
Study Suggests Lower Cement Leakage Rate with DFINE Radiofrequency Targeted Vertebral Augmentation(TM) (RF-TVA) in the Treatment of Vertebral Compression Fractures
Devices Neurosurgery Orthopaedic Radiology
 HSMN NewsFeed - 18 May 2011
Molecular Response Appoints Kenna Anderes, PhD, as Senior Vice President of Translational Medicine
Diagnostics Personnel
 HSMN NewsFeed - 17 May 2011
Pfizer Announces Simultaneous Filing Of New Drug Applications For Crizotinib With U.S. Food And Drug Administration And Japanese Ministry Of Health, Labour And Welfare
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Mar 2011
Cell Therapeutics Acquires Exclusive Marketing and Co-Development Rights in the Americas to Chroma Therapeutics' Tosedostat, a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 12 Jan 2011
Caris Life Sciences Launches Caris Target Now(TM) Ovarian Profile
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 13 Dec 2010
XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2010
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Dec 2010
Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Dec 2010
SUTENT(R) Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Nov 2010
Study in NEJM Shows Novartis Drug Afinitor(R) Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2010
Novartis Drug Afinitor(R) Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 11 Oct 2010
Phase III Novartis Data Show Potential Benefit of Afinitor(R) Plus Sandostatin(R) LAR Depot in Patients with Advanced Carcinoid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Aug 2010
RMD Instruments and Cunningham Woodland Announce Distribution Agreement for Navigator System and Surgical Probes
Devices Surgery Oncology Distribution
 HSMN NewsFeed - 29 Jul 2010
Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2010
Phase III Study Shows Novartis Drug Afinitor(R) More Than Doubles Time Without Tumor Growth in Advanced Pancreatic NET Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jun 2010
Calistoga Pharmaceuticals Raises $40 Million in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Jun 2010
Immunomedics Reports Updated Results of Targeted Therapy for Advanced Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2010
Trubion Pharmaceuticals Wins Genentech and Biogen Idec Patent Appeal
Biopharmaceuticals Litigation
 HSMN NewsFeed - 3 Jun 2010
Pivotal Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 May 2010
Researchers at MD Anderson Show That Positron Emission Mammography (PEM) Helps Evaluate Early Response to Neoadjuvant Chemotherapy
Devices Radiology Oncology
 HSMN NewsFeed - 1 Sep 2009
FDA Clears Hologic's MammoSite(R) ML Radiation Therapy System for the Treatment of Early-Stage Breast Cancer
Devices Oncology FDA
 HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2009
Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Mar 2009
El Camino Hospital Launches Genomic Medicine Institute
Diagnostics Hospitals & Healthcare Systems
 HSMN NewsFeed - 2 Feb 2009
Molecular Insight Pharmaceuticals Announces Board and Senior Management Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Nov 2008
Tarceva(R) (erlotinib) Endorsed by the U.K.'s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Nov 2008
NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2008
Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2008
Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Oct 2008
Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
Diagnostics FDA
 HSMN NewsFeed - 18 Sep 2008
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Aug 2008
Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Aug 2008
Lung Cancer Epidemic Looming in Asia?
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jul 2008
Nexavar Approved for Liver Cancer in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jul 2008
Tomas Leanderson appointed new President & CEO for Active Biotech
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jul 2008
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Jun 2008
Combination Therapy of Solvent-Free ABRAXANE(R) and the Targeted Therapy Bevacizumab Evaluated as First-Line Treatment for Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2008
New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Mar 2008
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Mar 2008
FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Feb 2008
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2007
OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Nov 2007
ARIAD Expands Leadership Team with Three New Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Oct 2007
Thallion Provides Update on Shigamabs(R) Clinical Development and U.S. Regulatory Plan
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2007
Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Oct 2007
GE and Lilly Announce Research Collaboration to Co-Develop Molecular In Vitro Diagnostics for Cancer Treatments
Diagnostics Oncology
 HSMN NewsFeed - 1 Oct 2007
Synvista Therapeutics Appoints Carl M. Mendel, M.D. Vice president, Clinical Development and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Sep 2007
FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Sep 2007
OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Sep 2007
OSI Pharmaceuticals Summarizes Data Presented on Tarceva(R) (erlotinib) at the 12th World Congress on Lung Cancer Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2007
Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Aug 2007
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jun 2007
Teva and Active Biotech to Initiate Pivotal Phase III Trial Program of Oral Laquinimod for Relapsing Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Jun 2007
OSI Pharmaceuticals Summarizes Data on Tarceva(R) (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
Data Published in the New England Journal of Medicine Showed TORISEL Extended Median Overall Survival for Patients with Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2007
Oncophage(R) Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 May 2007
Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Apr 2007
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva(R) Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Apr 2007
Thallion Pharmaceuticals Inc. Hires Executive Vice-President, Licensing and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Apr 2007
Thallion Presents Data at the 2007 Annual Meeting of the American Association of Cancer Research on its Oncology Drug Candidates ECO-4601 and CAP-232
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Apr 2007
Genta Announces New Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2007
FDA Approves TYKERB(R) (lapatinib) in Combination With Xeloda(R) (capecitabine) for the Treatment of Advanced or Metastatic Breast Cancer in Women Who Have Progressed on Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Feb 2007
Vaccinex Announces Antibody Development and Commercialization Alliance in Multiple Sclerosis and Oncology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Feb 2007
United Therapeutics Announces Pulmonary Hypertension Opinion Leaders' Guidance On Intravenous Therapies
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2007
Tapestry Pharmaceuticals Appoints Sandra L. Silberman, M.D., Ph.D. As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Feb 2007
Genta Completes Response to EMEA List of Outstanding Issues for Genasense(R) Marketing Authorization Application in Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Jan 2007
OSI Pharmaceuticals Announces European Regulatory Approval of Tarceva(R) for Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Jan 2007
Ventana Receives FDA Approval for Rabbit Monoclonal Antibody
Diagnostics Oncology FDA
 HSMN NewsFeed - 4 Jan 2007
Ecopia Announces Agreement with Caprion to Combine their Businesses and Launch a $30 Million Private Placement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Dec 2006
Anthracyclines May Not Be for Everyone: Report From the 29th Annual San Antonio Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2006
OSI Pharmaceuticals Announces That Tarceva(R) Received Positive Opinion from Health Authorities in European Union for the Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Dec 2006
New England Journal of Medicine Publishes Data from Pivotal Study of Avastin Plus Chemotherapy in Most Common Type of Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2006
Caprion Pharmaceuticals Announces Expansion of Biomarker Discovery Collaboration with Vertex Pharmaceuticals
Biopharmaceuticals
 HSMN NewsFeed - 17 Oct 2006
Introgen's ADVEXIN Molecular Targeted Therapy Is Active in Multiple Cancers; ADVEXIN Regulatory Program Advances
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2006
Hana Biosciences Licenses Drug Candidate for the Prevention and Treatment of EGFR Inhibitor-Associated Skin Rash
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 12 Oct 2006
Agennix Receives FDA Orphan Drug Designation for Talactoferrin Alfa in Renal Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2006
Michael A. Sherman Joins Endocyte as CFO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Oct 2006
Final Data From Two Phase II Trials Indicate Activity of Adecatumumab (MT201) in Breast and Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Sep 2006
FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2006
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Sep 2006
Final Report of Genasense Phase 3 Trial in Melanoma Published in Journal of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Sep 2006
Schering AG and AstraZeneca Form Strategic Alliance to Develop Novel Anti-Cancer Drug
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Aug 2006
Genentech and Biogen Idec Announce Positive Results From a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Aug 2006
MedImmune and Infinity Pharmaceuticals Announce Cancer Drug Development and Worldwide Commercialization Agreement
Biopharmaceuticals
 HSMN NewsFeed - 28 Jul 2006
OSI Pharmaceuticals Announces That Roche Has Received Negative CHMP Opinion in European Union on Tarceva(R) in Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Jun 2006
The International Myeloma Foundation Says REVLIMID(R) Approval for Multiple Myeloma Can Be Life-Changing for Cancer Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2006
Patients With Treatment-Resistant Leukemia Achieve High Responses to Tasigna(R) (nilotinib) in First Published Clinical Trial Results
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2006
Results From a Randomized Phase II Trial Suggested the Combinations of Avastin(R) Plus Tarceva(R) and Avastin Plus Chemotherapy Improved Progression- Free Survival in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2006
Serum HER-2/neu Change Predicts Clinical Outcome to Trastuzumab-Based Therapy
Oncology Diagnostics
 HSMN NewsFeed - 2 Jun 2006
Introgen's ADVEXIN p53 Therapy Demonstrates Clinical Benefit in Inherited Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 May 2006
Five years after approval, Gleevec underscores the promise of targeted therapy to provide sustained disease control
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 May 2006
Introgen's ADVEXIN p53 Therapy Provided to Cancer Patients With Li-Fraumeni Syndrome
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Apr 2006
OSI Pharmaceuticals Announces Submission of New Drug Application for Tarceva(R) in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Apr 2006
Cephalon Oncology Compound Lestaurtinib (CEP-701) Granted Orphan Drug Designation for Acute Myeloid Leukemia
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 27 Mar 2006
SGX Pharmaceuticals Announces Strategic Collaboration to Develop and Commercialize BCR-ABL Inhibitors for the Treatment of Chronic Myelogenous Leukemia (CML)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 15 Mar 2006
U.S. Food and Drug Administration Clears Innovative Cardiac Navigation Technology
Devices Cardiology FDA
 HSMN NewsFeed - 17 Jan 2006
Genta Appoints Seasoned Pharma Executive, Lloyd Sanders, as Vice-President for Sales and Marketing
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Jan 2006
Genta Completes Marketing Authorization Application to EMEA for Approval of Genasense(R) plus Chemotherapy for Patients with Advanced Melanoma
Biopharmaceuticals Oncology Regulatory
Return to NewsFeed  

 Additional items found! 65

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 65 additional stories matching:
targeted therapy
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.